Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 20

1.

Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.

Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M.

J Nucl Med. 2011 Aug;52(8):1276-84. doi: 10.2967/jnumed.111.087700. Epub 2011 Jul 15. Erratum in: J Nucl Med. 2011 Sep;52(9):1498.

2.

[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.

Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, von Guggenberg E, Pichler BJ, Virgolini I, Decristoforo C, Haubner R.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1303-12. doi: 10.1007/s00259-011-1778-0. Epub 2011 Apr 13.

PMID:
21487838
3.

Ligands for mapping alphavbeta3-integrin expression in vivo.

Schottelius M, Laufer B, Kessler H, Wester HJ.

Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b.

PMID:
19489579
4.

Radiolabelled RGD peptides and peptidomimetics for tumour targeting.

Haubner R, Decristoforo C.

Front Biosci (Landmark Ed). 2009 Jan 1;14:872-86. Review.

PMID:
19273105
5.

Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET.

Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M.

J Nucl Med. 2008 Feb;49(2):255-9. doi: 10.2967/jnumed.107.045526. Epub 2008 Jan 16.

6.

Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M.

J Nucl Med. 2008 Jan;49(1):22-9. Epub 2007 Dec 12.

7.

[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck.

Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6.

8.

Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M.

Clin Cancer Res. 2006 Jul 1;12(13):3942-9.

9.

Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M.

J Nucl Med. 2005 Aug;46(8):1333-41.

10.

Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.

Haubner R, Wester HJ.

Curr Pharm Des. 2004;10(13):1439-55. Review.

PMID:
15134568
11.

Integrins: roles in cancer development and as treatment targets.

Jin H, Varner J.

Br J Cancer. 2004 Feb 9;90(3):561-5. Review.

12.

Alpha(v)beta(3) integrin in angiogenesis and restenosis.

Kerr JS, Mousa SA, Slee AM.

Drug News Perspect. 2001 Apr;14(3):143-50.

PMID:
12819820
13.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
14.

alphav Vitronectin receptors in vascular-mediated disorders.

Mousa SA.

Med Res Rev. 2003 Mar;23(2):190-9. Review.

PMID:
12500288
15.
16.
17.

Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.

Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M.

J Nucl Med. 2001 Feb;42(2):326-36.

18.

Integrins and bone--cell adhesion and beyond.

Grzesik WJ.

Arch Immunol Ther Exp (Warsz). 1997;45(4):271-5. Review.

PMID:
9523000
19.

Tumor angiogenesis and the role of vascular cell integrin alphavbeta3.

Varner JA, Cheresh DA.

Important Adv Oncol. 1996:69-87. Review.

PMID:
8791129
20.

Integrins: versatility, modulation, and signaling in cell adhesion.

Hynes RO.

Cell. 1992 Apr 3;69(1):11-25. Review. No abstract available.

PMID:
1555235

Supplemental Content

Support Center